OncoScreen® Plus Cancer Mutation Profiling Tissue Kit
CE-IVDD
CE-Marked 518-gene panel that covers cancer related genes targeted by commercialized and investigational drugs.
Enables detection of mutations (SNV, InDel, CNV, Fusion, MSI and TMB) associated with pan-solid tumors.
An all-in-one genomic testing solution for immunotherapy and targeted therapy.
Key Features and Benefits
Performance Validations
Accuracy
197 clinical samples and commercial references, TSO500, ddPCR, Fluorescent PCR-Capillary Electerophoresis and WES AS comparative methologies For SNV/INDEL/CNV/Fusion/MSI: PPA > 97.0%,NPA > 99.0%
Specificity
83 benign tumors of 12 tissue types, pathological evaluation as comparative methodology For SNV/INDEL: NPA > 95.8%; For Fusion: > 98.9%; For CNV/MSI: NPA= 100%
Biomarker Panels
Clinically-significant Biomarkers Covered in OncoScreen ® Plus (518 Genes Panel)
By submitting this form, or by checking the box above the “Submit” button (if applicable),
you agree that your information will be processed according to Burning Rock’s privacy policy
to provide you with the information and/or general marketing communications (if applicable)
you have requested here. Burning Rock Dx is committed to protecting and respecting your
privacy.
We would like to collect certain personal information about you through cookies and similar technologies
in order to personalize the site for you, improve the performance of the site, and support our marketing
efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your
personal information in accordance with our Privacy Policy, which may include
online targeted and social media advertising in some instances. You can by clicking “Reject All”, you
can reject all cookies except for Strictly Necessary Cookies."